5 Early Symptoms Of Type 2 Diabetes That Can Be Confused For Other Conditions

Type 2 diabetes usually begins subtly, with symptoms that can be easily mistaken for other common conditions. Read on to know ...
Medical Dialogues

ERCP Complications, ICU infections: Bengaluru hospital, HoD Critical care medicine, gastroenterologist slapped Rs 30 lakh compensation

Hassan, recently directed a Bengaluru-based hospital and its two doctors to pay Rs 30 lakh compensation to the family of ...

'Indicator of something serious': Patients warned to keep a close eye on the colour of their pee

A leading pharmacist has urged patients to keep a close eye on the colour of their urine, which can provide vital clues to ...

I spent five months thinking I was going to die — the truth was unbelievable

This marked the beginning of a five-month-long journey, that saw her develop a piercing headache that wouldn’t go away, ...
Le Lézard

Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...
Central Illinois Proud

Overactive Bladder: Insights from Carle Health urologist Robert Lai | Ask The Doc

Carle Health Urologist, Dr. Robert Lai, discussed Overactive Bladder (OAB) during Overactive Bladder Awareness Month.

FDA Grants Full Approval To Amgen's Imdelltra In Extensive Stage Small Cell Lung Cancer

Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard ...
EuropaWire

AstraZeneca Secures FDA Approval for Koselugo to Treat Adults with NF1 Plexiform Neurofibromas Following Positive Phase III KOMET Results

AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...